Literature DB >> 20797908

T cell vaccination therapy in an induced model of anti-RNP autoimmune glomerulonephritis.

Sapna Trivedi1, YunJuan Zang, Schartess Culpepper, Erica Rosenbaum, Irina Fernandez, Laisel Martinez, Robert W Hoffman, Eric L Greidinger.   

Abstract

To establish the relevance of targeting disease-associated T cells in anti-RNP-associated glomerulonephritis, mice developing nephritis following immunization with U1-70-kd small nuclear ribonucleoprotein (snRNP) were treated with a single dose of irradiated antigen-selected T cell vaccine. T cell receptor usage in nephritic kidneys revealed oligoclonal use of T Cell Receptor V Beta (TRBV) genes as previously found in spleens and lungs of immunized mice with pulmonary disease. The CDR3 regions from T cell isolates showed sequence homology to those in humans with anti-RNP autoimmunity. Following T cell vaccination, urinalysis returned to normal in 5/7 treated mice (71% response rate) whereas all mock-treated mice continued to have an active urinary sediment (Fisher's Exact p=0.02). An oligoclonal population of T cells homologous to those identified in humans with anti-RNP autoimmunity is implicated in disease pathogenesis, and T cell vaccination is associated with a high rate of clinical improvement in established nephritis. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797908      PMCID: PMC2950256          DOI: 10.1016/j.clim.2010.07.013

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  19 in total

1.  Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule.

Authors:  Eric L Greidinger; Mark F Foecking; Sriya Ranatunga; Robert W Hoffman
Journal:  Arthritis Rheum       Date:  2002-05

2.  Structural analysis of TCRalpha and beta chains from human T-Cell clones specific for small nuclear ribonucleoprotein polypeptides Sm-D, Sm-B and U1-70 kDa: TCR complementarity determining region 3 usage appears highly conserved.

Authors:  B L Talken; C W Bailey; S L Reardon; C W Caldwell; R W Hoffman
Journal:  Scand J Immunol       Date:  2001 Jul-Aug       Impact factor: 3.487

3.  Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.

Authors:  G C Sharp; W S Irvin; C M May; H R Holman; F C McDuffie; E V Hess; F R Schmid
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

4.  Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.

Authors:  Takao Fujii; Masato Okada; Yoshimasa Fujita; Takeshi Sato; Masao Tanaka; Takashi Usui; Hisanori Umehara; Tsuneyo Mimori
Journal:  J Autoimmun       Date:  2009-07-12       Impact factor: 7.094

5.  Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production.

Authors:  Eric L Greidinger; Tal Gazitt; Kimberly F Jaimes; Robert W Hoffman
Journal:  Arthritis Rheum       Date:  2004-07

6.  Tissue targeting of anti-RNP autoimmunity: effects of T cells and myeloid dendritic cells in a murine model.

Authors:  Eric L Greidinger; Yunjuan Zang; Irina Fernandez; Mariana Berho; Mehdi Nassiri; Laisel Martinez; Robert W Hoffman
Journal:  Arthritis Rheum       Date:  2009-02

7.  Cloned human TCR from patients with autoimmune disease can respond to two structurally distinct autoantigens.

Authors:  Mihiri De Silva-Udawatta; Senthil R Kumar; Eric L Greidinger; Robert W Hoffman
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

8.  Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.

Authors:  Lena Schiffer; Jayashree Sinha; Xiaobo Wang; Weiqing Huang; Gero von Gersdorff; Mario Schiffer; Michael P Madaio; Anne Davidson; Gero Von Gonsdorff
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

Authors:  Sylviane Muller; Fanny Monneaux; Nicolas Schall; Rasho K Rashkov; Boycho A Oparanov; Philippe Wiesel; Jean-Marie Geiger; Robert Zimmer
Journal:  Arthritis Rheum       Date:  2008-12

10.  T cell immunity in connective tissue disease patients targets the RNA binding domain of the U1-70kDa small nuclear ribonucleoprotein.

Authors:  Eric L Greidinger; Mark F Foecking; Kim R Schäfermeyer; Craig W Bailey; Shannon L Primm; David R Lee; Robert W Hoffman
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

View more
  4 in total

1.  Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy.

Authors:  YunJuan Zang; Laisel Martinez; Irina Fernandez; Judith Pignac-Kobinger; Eric L Greidinger
Journal:  J Immunol       Date:  2014-03-26       Impact factor: 5.422

2.  Regulatory T cells play a role in T-cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis.

Authors:  Abigail C Buenafe; Shayne Andrew; Halina Offner; Arthur A Vandenbark
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

3.  CD8+ regulatory T cells induced by T cell vaccination protect against autoimmune nephritis.

Authors:  Yuan Min Wang; Geoff Yu Zhang; Min Hu; Tania Polhill; Andrew Sawyer; Jimmy Jianheng Zhou; Mitsuru Saito; Debbie Watson; Huiling Wu; Ya Wang; Xin Maggie Wang; Yiping Wang; David C H Harris; Stephen I Alexander
Journal:  J Am Soc Nephrol       Date:  2012-04-05       Impact factor: 10.121

Review 4.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.